The EMLc Subcommittee noted that there is an emerging need for oral anti diabetic drugs suitable for children due to the increasing obesity epidemic and increasing Type II diabetes in children. The Subcommittee noted that glibenclamide and metformin were still primarily used in adult populations for Type II diabetes. The potential need of these medicines in adolescents and children was recognized. The Subcommittee decided not to include glibenclamide in the EMLc at present. The Subcommittee decided to include metformin in the EMLc on the complementary list. This area should be reviewed at a subsequent meeting taking into account available medicines and the changing epidemiology of Type II diabetes in children under 12 years.